Featured Article Academic Journal Main Category: Neurology / Neuroscience Also Included In: Psychology / Psychiatry Article Date: 21 Sep 2013 - 0:00 PDT

Current ratings for: Gene that triggers 'memory extinction' discovered

5 (3 votes)

4.92 (13 votes)

Many of us are the bearers of "bad" memories that, to this day, continue to affect our lives. Now, scientists say they have discovered a gene essential for "memory extinction," the process by which our brain replaces older memories with new experiences.

Researchers from the Massachusetts Institute of Technology (MIT) say the discovery could help people suffering from post-traumatic stress disorder (PTSD) by replacing "fearful" memories with more positive associations.

The gene, Tet1, has been found to play a critical role in memory extinction by controlling a small group of other genes that are necessary for the process.

For the study, published in the journal Neuron, the research team experimented on mice who had the Tet1 gene "knocked out," as well as on mice who had normal levels of the gene.

In order to measure the mice's ability to abolish memories, the mice were "conditioned" to fear a certain cage in which they received a small electric shock. Once the memory of the "cage shock" was formed, the mice were placed into the cage, but the researchers did not give them the shock.

The researchers found that after a period of time, mice with normal Tet1 levels appeared to lose their fear of the cage, indicating that new memories replaced the old ones.

Excerpt from:
Gene that triggers 'memory extinction' discovered

Recommendation and review posted by Bethany Smith

PEMBROKE Genetic engineering, climate change and history were all on the menu as an environmental activist and former two-time vice presidential candidate shared what she called the covenant American Indians have with their food.

About 60 students and faculty from The University of North Carolina at Pembroke and local residents came to The Regional Center at COMtech to hear Winona LaDukes presentation on ecological sustainability and self-sufficiency on Thursday. The presentation was part of UNCPs Native American Speakers Series and the 2013 Conference of American Indian Women of Proud Nations, which began Wednesday and concludes today.

LaDuke, an Anishinaabe Indian, said food is a lifeline to Americans Indians culture and heritage, saying the Anishinaabe tribe was told to go to where food grows on the water, which led them to the rice paddies of Minnesota. She highlighted her point in a video showing Anishinaabe men harvesting wild rice during an annual ritual on their reservation.

Its not just a commodity, LaDuke said. Its a covenant.

To protect that bond, LaDuke said she and her family waged an eight-year battle against the federal government to stop the genetic engineering of indigenous wild rice.

If genetic engineering is the answer, what was the question? she said.

LaDuke said climate change and the use of fossil fuels are causing ecological ruin around the world, especially with the way fuels are extracted from the Earth.

Carbon belongs in the soil, not in the air, she said. When you go to extremes, you do things like frack and blow the tops off of 500 mountains because youre desperate.

LaDuke showed photos of houses in an Alaskan village crumbling because the foundation underneath is melting, which she said is evidence that geography is changing.

Anyone who thinks climate change isnt happening is highly delusional, she said.

See the original post:
Indian activist says answers to Earth’s woes found in dirt -

Recommendation and review posted by Bethany Smith

Irvine, CA (PRWEB) September 20, 2013

Proove Biosciences, Inc., the leading personalized pain medicine laboratory, is excited to announce that they will be attending and exhibiting at the California Society of Interventional Pain Physicians 4th Annual Meeting this weekend at the Terranea Resort in Rancho Palos Verdes, California. The event will be held from September 20th to September 22nd.

CASIPP is a growing advocacy society working for interventional pain management physicians and their staff within the state of California. The organizations mission is to promote the development and practice of safe, high quality, cost-effective interventional pain medicine techniques for the diagnosis and treatment of pain and related disorders, and ensure patient access to these interventions.

We are proud to support Dr. Ray d'Amours, the President and Executive Director of CASIPP in this important conference, explains Proove CEO and founder, Brian Meshkin. Proove is a research-driven company committed to realizing the potential of personalized pain medicine. We are proud to stand with Dr. dAmours and his colleagues at the forefront of pain medicine genetics. We continue to be the only company to present clinical research on the genetics of pain medicine at scientific meetings throughout the year including, PAINWeek, the American Pain Society, American Society of Addiction Medicine, and other major scientific meetings on pain management.

Proove Biosciences will be exhibiting at CASIPP and sharing information on its proprietary genetic testing services, including the Proove Narcotic Risk Genetics test that helps physicians identify genetic predisposition to misuse of prescription narcotic pain medications and the Proove Drug Metabolism Genetics test that helps physicians understand the genetic predisposition to drug metabolism.

The meeting will consist of a variety of lectures, workshops, and speakers that cover topics ranging from pain management and therapy optimization, to the current political landscape of California pain management and treatment. Additionally, there will be opportunities for Continued Medical Education (CME) credit.

About Proove Biosciences Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

See original here:
Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting ...

Recommendation and review posted by Bethany Smith

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 28
My Sims 3 Page: http://mypage.thesims3.com/mypage/Llandros2012 My Blog: http://Llandros09.blogspot.com My Facebook: https://www.facebook.com/Llandros09?ref=t...

By: Llandros09

Read the original here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 28 - Video

Recommendation and review posted by Bethany Smith

2014 Genetics
Meds for 2014.

By: CultivatedCaregivers

Read the original:
2014 Genetics - Video

Recommendation and review posted by Bethany Smith

LOS ANGELES, Sept. 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.

The offering is expected to close on or about September 25, 2013, subject to the satisfaction of customary closing conditions. Response Genetics intends to use the net proceeds from the offering primarily to expedite the integration of the recently acquired proprietary FDA-cleared and Medicare-reimbursed Tissue of Origin test for difficult to diagnose solid tumors and all associated assets, as more fully described in the Company's press release dated August 26, 2013 and related Form 8-K.

"This additional capital is primarily intended to facilitate a focused and expedited integration of this portfolio enhancing product," said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. "In conjunction with this effort, we are excited to begin immediate construction of additional laboratory space in our Los Angeles facility. We intend to offer this proprietary Tissue of Origin test, Response Dx: TOOTM, to new and existing customers starting in the first quarter of 2014."

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as the placement agent for this offering.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the registration statement, final base prospectus and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission's website at http://www.sec.gov or from Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, New York 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Visit link:
Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGIX" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, was featured in an article in USA TODAY titled "Targeted therapy and companion diagnostics go hand and hand." The article is available online at:

http://us.mediaplanet.com/future-of-cancer-care/hand-in-hand-how-targeted-therapy-and-companion-diagnostics-are-changing-outcomes-for-cancer-patients

Additionally, the September 20 print edition of USA TODAY features a panel discussion with Dr. Raju Chaganti, founder and chairman of CGIX. In the panel discussion, Dr. Chaganti and other leading oncology experts share insights about advancements that are impacting the future of cancer care.

The panel discussion includes information on the newest diagnostic and treatment options available to patients, how changes in technology have impacted cancer care, forecasts for new technology advancements, and other topics driving innovation in the industry.

"The Future of Cancer Care" insert will be available in print editions of USA TODAY on September 20 in the following markets: New York City, Philadelphia, Washington D.C., Baltimore, Cincinnati and Chicago. USA TODAY online sites have 26.3 million unique visitors per month. An online version of the insert is available at:

http://us.mediaplanet.com/future-of-cancer-care/

A PDF of the insert as featured in USA TODAY is available at:

http://doc.mediaplanet.com/all_projects/12832.pdf

CGIX is a sponsor of "The Future of Cancer Care" insert.

About Cancer Genetics:

View original post here:
Cancer Genetics, Inc. Featured in USA TODAY Article

Recommendation and review posted by Bethany Smith

ATLANTA, GA--(Marketwired - Sep 20, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS) is proud to announce its sponsorship of The Third Annual Power of Pink luncheon, fashion show and silent auction. The event will take place at the Country Club of the South in Johns Creek, Georgia, on Friday, September 20, 2013.

This year, North Fulton Hospital, through its Check-Up for Chicks program, is again taking a stand in the fight against breast cancer with the Power of Pink. More than 300 of North Atlanta's most passionate supporters of breast health and breast cancer research will be in attendance.

"We are proud to sponsor this important annual event in the quest to raise breast cancer awareness and fight this devastating disease," stated Chris Destro, VP of Sales & Marketing at Atossa. In addition to sponsoring events and supporting efforts like Power of Pink, we are contributing to the fight against breast cancer with the national rollout of our ForeCYTE Breast Health Test. The ForeCYTE test is a revolutionary new product that detects reversible precancerous conditions in the breastapproximately 8years before they become cancer, enabling physicians and their patients to obtain valuable, science-based information to manage their breast health."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office.The test can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.For more information, please visit getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit http://www.atossagenetics.com and http://www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit http://www.getforecyte.com.

Link:
Atossa Genetics to Sponsor Power of Pink Event in Johns Creek, Georgia

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Tai Chi Practice

By: Jeffery Morris

Go here to read the rest:
Spinal Cord Injury Tai Chi Practice - Video

Recommendation and review posted by sam

Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Stamina has improved. 2. Fatigue is...

By: Neurogen Brain and Spine Institute

Originally posted here:
Stem Cell Therapy Treatment for Spino Muscular Atrophy by Dr Alok Sharma, Mumbai, India - Video

Recommendation and review posted by simmons

Strides in Heart Care: Personalized Medicine - PREDICT
Vanderbilt Heart doctors, nurses and patients explain how patients and families can benefit from the next wave of technology and treatment options. To learn ...

By: Vanderbilt Health

Link:
Strides in Heart Care: Personalized Medicine - PREDICT - Video

Recommendation and review posted by sam

Can you Get Disability Benefits for a Spinal Cord Injury Claim?
In this Video Marc Whitehead, a Board Certified Disability Attorney, explains whether or not you are able to get disability benefits for a spinal cord injury.

By: Marc Whitehead

Continued here:
Can you Get Disability Benefits for a Spinal Cord Injury Claim? - Video

Recommendation and review posted by sam

Nurturing the science behind regenerative medicine
Speakers Dr Paul Fairchild, Oxford Stem Cell Institute Further Information October 2008: Showcase: Oxford Stem Cell Institute - Dr Paul Fairchild Oxford Mart...

By: 21school

Continue reading here:
Nurturing the science behind regenerative medicine - Video

Recommendation and review posted by sam

ONE Musicfest 2013, Goodie Mob "Cell Therapy"
ONE Musicfest 2013 (www.onemusicfest.com), snippet of Goodie Mob performing "Cell Therapy."

By: koolnessnofoolness

Read the original post:
ONE Musicfest 2013, Goodie Mob "Cell Therapy" - Video

Recommendation and review posted by Bethany Smith

SYDNEYand AUCKLAND, New Zealand, Sept. 19, 2013 /PRNewswire/ --Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) a potential treatment for Parkinson's disease.

The pioneering brain surgery was conducted at Auckland City Hospital and the patient has recovered well so far. An MRI scan taken the day after the surgery indicated that the NTCELL capsules have been implanted at their intended target. The patient and family have requested privacy and no contact with the media.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson's disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed.

The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinson's disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. "The team are pleased with how well the patient tolerated the procedure itself," says Dr Snow. "The surgery is relatively straightforward in neurosurgery terms, and we have taken full advantage of well-established techniques, which lowers the clinical risk. The patient will now be monitored closely by the team over the next two months."

Dr Andrea Grant, CEO and Managing Director of LCT says: "This is a significant milestone and a world first. It has taken a great deal of hard work, clinical and scientific endeavour to get to this and so of course we are excited. The purpose of this "first-in-man" study is to demonstrate the treatment is safe. Provided this trial is succesful, future trials will further assess the extent of clinical benefit that patients might gain."

In the clinical trial, NTCELL is injected under guidance by neuroimaging into the affected area of the human brain where substantial death of neurons and other cells has occurred. The cell therapy is comprised of choroid plexus cells, which are naturally occurring 'support' cells for the brain. LCT's propriety technology IMMUPEL(R) coats the implanted cells to protect them from attack by the patient's immune system.

The scientific basis for the Phase I clinical trial in humans was established from the published preclinical trial of NTCELL(R) in a non-human primate model of Parkinson's disease. The preclinical results indicate that NTCELL can protect and regenerate brain tissue that would otherwise be lost, potentially delaying or even preventing the effects of Parkinson's disease.

"Unlike current therapy options for Parkinson's disease, NTCELL may be neuroprotective and offers people living with the disease the hope of being able to halt disease progression and restore quality of life," says Dr Grant.

LCT and Otsuka Pharmaceutical Factory (OPF) are co-developing NTCELL as a treatment for Parkinson's disease. Under the agreement, LCT has already received an A$3m cash payment and OPF is funding all of the research and development costs associated with the Phase I clinical trial, estimated at AU$2.1m. In addition, LCT will receive a second cash payment of AU$2m provided the DSMB authorise the remaining three implants later in the year.

For further information: http://www.lctglobal.com

Read more:
'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease

Recommendation and review posted by Bethany Smith

Public release date: 19-Sep-2013 [ | E-mail | Share ]

Contact: Sarah Smith sas2072@med.cornell.edu 646-317-7401 Weill Cornell Medical College

NEW YORK (September 19, 2013) -- Researchers at Weill Cornell Medical College have discovered why a tiny alteration in a brain gene, found in 20 percent of the population, contributes to the risk for anxiety, depression and memory loss.

Their discovery, reported in Nature Communications, describes new functions for the alteration, a single nucleotide polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene. This gene is a powerful regulator of the growth and function of neurons, and the establishment of brain circuitry. The common alteration occurs when a single "letter" of BDNF's genetic code is "misspelled."

The team of investigators, led by Dr. Clay Bracken, associate research professor of biochemistry and director of the nuclear magnetic resonance facility, Dr. Barbara Hempstead, professor of medicine, and Dr. Francis Lee, professor of psychiatry, all at Weill Cornell Medical College, discovered that the alteration appears to induce shrinkage of neurons from the hippocampus (an important region for memory and emotion), reducing connectivity between brain cells.

The discovery upends the prevailing theory about how the BDNF SNP alters the function of the brain, says Dr. Agustin Anastasia, first author of the article and a postdoctoral fellow in the Hempstead lab. "Research on BDNF is very active worldwide, and the conventional wisdom of the field was that the SNP reduced the amount of BDNF that was secreted. Therefore, many investigators were trying to increase production of the protein -- but this effort was only moderately successful."

"While the SNP does decrease the amount of BDNF in neurons, it generates a protein, the Met66 prodomain, that is different from the Val66 prodomain that is generated by the 80 percent of the human population that does not carry the SNP," Dr. Hempstead says. "The Met66 prodomain binds to specific proteins on the surface of neurons, to induce the pruning or shrinkage of these neurons."

The findings offer mechanistic insight into why some depression and anxiety runs in families, Dr. Lee says. "There can be a heritable component to these diseases and it makes sense that a common variant in a gene could be involved," he says. "Just like hypertension contributes to the risk for heart disease, the BDNF alteration increases the risk of depression, anxiety and memory disorders -- but is not the sole reason why they occur."

Still, targeted treatment for the genetic alteration could provide the first true benefit for affected patients, who often don't respond to traditional treatments, Dr. Lee says. "We can easily test patients for the mutation by using a simple blood test," he says. "We just need novel targeted treatments that alter the effects of the BDNF SNP-- and now we have a good lead on what that therapy should do."

The other half of the story

Read more here:
Researchers tease apart workings of a common gene

Recommendation and review posted by Bethany Smith

London, Sept 20 : A team of researchers led by King's College London has for the first time identified a new gene which may have the ability to prevent HIV, the virus that causes AIDS, from spreading after it enters the body.

The study is the first to identify a role for the human MX2 gene in inhibiting HIV.

Researchers say this gene could be a new target for effective, less toxic treatments where the body's own natural defence system is mobilised against the virus.

The work was funded by the Medical Research Council and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The study was also supported by the Wellcome Trust and European Commission.

Scientists carried out experiments on human cells in the lab, introducing the virus to two different cell lines and observing the effects. In one cell line the MX2 gene was expressed or 'switched on', and in the other it was not, or 'silenced'.

They saw that in the cells where MX2 was silenced, the virus replicated and spread. In the cells where the MX2 gene was expressed, the virus was not able to replicate and new viruses were not produced.

The work was led by Dr Caroline Goujon and Professor Mike Malim at theDepartment of Infectious Diseases, King's College London.

Professor Malim said: "This is an extremely exciting finding which advances our understanding of how HIV virus interacts with the immune system and opens up opportunities to develop new therapies to treat the disease. Until now we knew very little about the MX2 gene, but now we recognise both its potent anti-viral function and a key point of vulnerability in the life cycle of HIV.

"Developing drugs to stimulate the body's natural inhibitors is a very important approach because you are triggering a natural process and therefore won't have the problem of drug resistance. There are two possible routes - it may be possible to develop either a molecule that mimics the role of MX2 or a drug which activates the gene's natural capabilities."

"Although people with HIV are living longer, healthier lives with the virus thanks to current effective treatments, they can often be toxic for the body and drug resistance can become an issue with long-term use. It is important to continue to find new ways of mobilising the body's natural defence systems and this gene appears to be a key player in establishing viral control in people with HIV."

View original post here:
Gene discovery may lead to new HIV treatments

Recommendation and review posted by Bethany Smith

The Ultimate Anti-Aging Tool - Wave Genetics by Dr. Peter Garyaev
http://wavegenetics.org/en - Wave Genetics by Dr. Peter Garyaev. Theory of wave genetics is the first scientific tool in the whole history of mankind that ca...

By: wavegenetics

Read the rest here:
The Ultimate Anti-Aging Tool - Wave Genetics by Dr. Peter Garyaev - Video

Recommendation and review posted by Bethany Smith

Diagnostic US Harms DNA. Dr. Peter Garyaev
http://wavegenetics.org/en Professor of Biology Peter Garyaev is the founding father of wave genetics — a truly revolutionary theory in modern science that c...

By: wavegenetics

Read more from the original source:
Diagnostic US Harms DNA. Dr. Peter Garyaev - Video

Recommendation and review posted by Bethany Smith

Boring Genetics class.

By: Lyla Misiam

See the article here:
Boring Genetics class. - Video

Recommendation and review posted by Bethany Smith

Barbara Franke - How to make sense of genetics for psychiatric disorders? (2013)
Keynote lecture at Neuroinformatics 2013 in Stockholm, Sweden Barbara Franke, Radboud University Medical Centre in Nijmegen, Nijmegen, The Netherlands.

By: INCForg

Originally posted here:
Barbara Franke - How to make sense of genetics for psychiatric disorders? (2013) - Video

Recommendation and review posted by Bethany Smith

Charleroi-Durable.be : Delphi Genetics
Activités High Tech dans un bâtiment passif ! Le développement durable selon Delphi Genetics , c #39;est ... - Un bâtiment passif, compatible avec une activité industrielle - Une valeur ajoutée,...

By: IgretecAnimEco

Read the rest here:
Charleroi-Durable.be : Delphi Genetics - Video

Recommendation and review posted by Bethany Smith

New Alex Collier: Alien Hybrid Genetics
Alex Collier Contactee abductee Alien reptilian agenda disclosed genetic influence hybrid racial interracial andromedan andromeda nibiru planet x anunnaki gr...

By: Disclosure TV

Read more:
New Alex Collier: Alien Hybrid Genetics - Video

Recommendation and review posted by Bethany Smith

Association for Molecular Pathology vs. Myriad Genetics - Arti Rai
September 9, 2013 - National Advisory Council for Human Genome More: http://www.genome.gov/27554864.

By: GenomeTV

Read more from the original source:
Association for Molecular Pathology vs. Myriad Genetics - Arti Rai - Video

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Panna Sharma, president and CEO of Cancer Genetics, Inc. (CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, provides insight and commentary on its expanding relationship with Roche Servicios, S.A., an affiliate of Swiss drug maker Roche, in this pre-recorded video interview. Click here to view:

Some key highlights covered in the interview with Mr. Sharma include:

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

View original post here:
CEO of Cancer Genetics, Inc. Provides Commentary on the Company's Expanded Relationship With Roche Servicios S.A.

Recommendation and review posted by Bethany Smith